Lumos Diagnostics Holdings Limited (LDX) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Recording in progress. Welcome to the Lumos Diagnostics FY25 Results Investor Briefing. My name is George Kopsiak. I'll be your moderator for today. The webinar is being recorded today and will be made available on the Lumos website over the next couple of days. With us this morning, we have Lumos Diagnostics CEO, Doug Ward. We have CFO, Barry Lambert. Paul Case is the Senior Vice President of Commercial Operations. And Annie Bell is our Vice President of Medical Affairs. Good morning to you all. Morning, George. Morning. So the format for today is for the team to walk you through the presentation that was released to the ASICs this morning. The presentation should take around 30 to 35 minutes. and this will then be followed by a question and answer session. If you'd like to ask a question, please click on the Q&A tab in the ribbon below, type your question in the box, and then I'll ask it on your behalf. That concludes housekeeping for today, so I'd like to now hand it over to Doug to get us started. Thank you, Doug. Thank you very much, George. Hello, everyone. Really pleased to be with you today to go through our year-end 2025 financials and a number of other updates that we've had and announcements that we've made over the last few weeks. This, quite frankly, I think is one of the most positive webinars that we've had to date, and we're really excited to bring you this today. And I'm really pleased to have both Paul and Annie with us. Given some of the detail in regard to sales as well as our clinical studies, I wanted to get them in front of you so that they can talk about the specifics of what we've actually done accomplished today and talk also about what's to come. So with that, why don't we move forward, Barrett? And then, so as always, I think, you know, fo...